62 related articles for article (PubMed ID: 38715141)
21. Cytoreduction for colorectal metastases: liver, lung, peritoneum, lymph nodes, bone, brain. When does it palliate, prolong survival, and potentially cure?
Stewart CL; Warner S; Ito K; Raoof M; Wu GX; Kessler J; Kim JY; Fong Y
Curr Probl Surg; 2018 Sep; 55(9):330-379. PubMed ID: 30526930
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With
Qin S; Li J; Wang L; Xu J; Cheng Y; Bai Y; Li W; Xu N; Lin LZ; Wu Q; Li Y; Yang J; Pan H; Ouyang X; Qiu W; Wu K; Xiong J; Dai G; Liang H; Hu C; Zhang J; Tao M; Yao Q; Wang J; Chen J; Eggleton SP; Liu T
J Clin Oncol; 2018 Oct; 36(30):3031-3039. PubMed ID: 30199311
[TBL] [Abstract][Full Text] [Related]
23. Effect of HK2, PKM2 and LDHA on Cetuximab efficacy in metastatic colorectal cancer.
Wang H; Peng R; Chen X; Jia R; Huang C; Huang Y; Xia L; Guo G
Oncol Lett; 2018 Apr; 15(4):5553-5560. PubMed ID: 29552193
[TBL] [Abstract][Full Text] [Related]
24. CircHIPK3 promotes colorectal cancer growth and metastasis by sponging miR-7.
Zeng K; Chen X; Xu M; Liu X; Hu X; Xu T; Sun H; Pan Y; He B; Wang S
Cell Death Dis; 2018 Apr; 9(4):417. PubMed ID: 29549306
[TBL] [Abstract][Full Text] [Related]
25. Silencing of hsa_circ_0007534 suppresses proliferation and induces apoptosis in colorectal cancer cells.
Zhang R; Xu J; Zhao J; Wang X
Eur Rev Med Pharmacol Sci; 2018 Jan; 22(1):118-126. PubMed ID: 29364478
[TBL] [Abstract][Full Text] [Related]
26. lncRNA MIR100HG-derived miR-100 and miR-125b mediate cetuximab resistance via Wnt/β-catenin signaling.
Lu Y; Zhao X; Liu Q; Li C; Graves-Deal R; Cao Z; Singh B; Franklin JL; Wang J; Hu H; Wei T; Yang M; Yeatman TJ; Lee E; Saito-Diaz K; Hinger S; Patton JG; Chung CH; Emmrich S; Klusmann JH; Fan D; Coffey RJ
Nat Med; 2017 Nov; 23(11):1331-1341. PubMed ID: 29035371
[TBL] [Abstract][Full Text] [Related]
27. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Venook AP; Niedzwiecki D; Lenz HJ; Innocenti F; Fruth B; Meyerhardt JA; Schrag D; Greene C; O'Neil BH; Atkins JN; Berry S; Polite BN; O'Reilly EM; Goldberg RM; Hochster HS; Schilsky RL; Bertagnolli MM; El-Khoueiry AB; Watson P; Benson AB; Mulkerin DL; Mayer RJ; Blanke C
JAMA; 2017 Jun; 317(23):2392-2401. PubMed ID: 28632865
[TBL] [Abstract][Full Text] [Related]
28. Silencing CDR1as inhibits colorectal cancer progression through regulating microRNA-7.
Tang W; Ji M; He G; Yang L; Niu Z; Jian M; Wei Y; Ren L; Xu J
Onco Targets Ther; 2017; 10():2045-2056. PubMed ID: 28435295
[TBL] [Abstract][Full Text] [Related]
29. Translation of CircRNAs.
Pamudurti NR; Bartok O; Jens M; Ashwal-Fluss R; Stottmeister C; Ruhe L; Hanan M; Wyler E; Perez-Hernandez D; Ramberger E; Shenzis S; Samson M; Dittmar G; Landthaler M; Chekulaeva M; Rajewsky N; Kadener S
Mol Cell; 2017 Apr; 66(1):9-21.e7. PubMed ID: 28344080
[TBL] [Abstract][Full Text] [Related]
30. Circular RNA ciRS-7-A Promising Prognostic Biomarker and a Potential Therapeutic Target in Colorectal Cancer.
Weng W; Wei Q; Toden S; Yoshida K; Nagasaka T; Fujiwara T; Cai S; Qin H; Ma Y; Goel A
Clin Cancer Res; 2017 Jul; 23(14):3918-3928. PubMed ID: 28174233
[No Abstract] [Full Text] [Related]
31. Circular RNAs are down-regulated in KRAS mutant colon cancer cells and can be transferred to exosomes.
Dou Y; Cha DJ; Franklin JL; Higginbotham JN; Jeppesen DK; Weaver AM; Prasad N; Levy S; Coffey RJ; Patton JG; Zhang B
Sci Rep; 2016 Nov; 6():37982. PubMed ID: 27892494
[TBL] [Abstract][Full Text] [Related]
32. HIF-1α pathway: role, regulation and intervention for cancer therapy.
Masoud GN; Li W
Acta Pharm Sin B; 2015 Sep; 5(5):378-89. PubMed ID: 26579469
[TBL] [Abstract][Full Text] [Related]
33. The genomic landscape of response to EGFR blockade in colorectal cancer.
Bertotti A; Papp E; Jones S; Adleff V; Anagnostou V; Lupo B; Sausen M; Phallen J; Hruban CA; Tokheim C; Niknafs N; Nesselbush M; Lytle K; Sassi F; Cottino F; Migliardi G; Zanella ER; Ribero D; Russolillo N; Mellano A; Muratore A; Paraluppi G; Salizzoni M; Marsoni S; Kragh M; Lantto J; Cassingena A; Li QK; Karchin R; Scharpf R; Sartore-Bianchi A; Siena S; Diaz LA; Trusolino L; Velculescu VE
Nature; 2015 Oct; 526(7572):263-7. PubMed ID: 26416732
[TBL] [Abstract][Full Text] [Related]
34. Exon-intron circular RNAs regulate transcription in the nucleus.
Li Z; Huang C; Bao C; Chen L; Lin M; Wang X; Zhong G; Yu B; Hu W; Dai L; Zhu P; Chang Z; Wu Q; Zhao Y; Jia Y; Xu P; Liu H; Shan G
Nat Struct Mol Biol; 2015 Mar; 22(3):256-64. PubMed ID: 25664725
[TBL] [Abstract][Full Text] [Related]
35. Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer.
Arena S; Bellosillo B; Siravegna G; Martínez A; Cañadas I; Lazzari L; Ferruz N; Russo M; Misale S; González I; Iglesias M; Gavilan E; Corti G; Hobor S; Crisafulli G; Salido M; Sánchez J; Dalmases A; Bellmunt J; De Fabritiis G; Rovira A; Di Nicolantonio F; Albanell J; Bardelli A; Montagut C
Clin Cancer Res; 2015 May; 21(9):2157-66. PubMed ID: 25623215
[TBL] [Abstract][Full Text] [Related]
36. MicroRNA-7 expression in colorectal cancer is associated with poor prognosis and regulates cetuximab sensitivity via EGFR regulation.
Suto T; Yokobori T; Yajima R; Morita H; Fujii T; Yamaguchi S; Altan B; Tsutsumi S; Asao T; Kuwano H
Carcinogenesis; 2015 Mar; 36(3):338-45. PubMed ID: 25503932
[TBL] [Abstract][Full Text] [Related]
37. Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution.
Misale S; Di Nicolantonio F; Sartore-Bianchi A; Siena S; Bardelli A
Cancer Discov; 2014 Nov; 4(11):1269-80. PubMed ID: 25293556
[TBL] [Abstract][Full Text] [Related]
38. circRNA biogenesis competes with pre-mRNA splicing.
Ashwal-Fluss R; Meyer M; Pamudurti NR; Ivanov A; Bartok O; Hanan M; Evantal N; Memczak S; Rajewsky N; Kadener S
Mol Cell; 2014 Oct; 56(1):55-66. PubMed ID: 25242144
[TBL] [Abstract][Full Text] [Related]
39. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Heinemann V; von Weikersthal LF; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Hielscher J; Scholz M; Müller S; Link H; Niederle N; Rost A; Höffkes HG; Moehler M; Lindig RU; Modest DP; Rossius L; Kirchner T; Jung A; Stintzing S
Lancet Oncol; 2014 Sep; 15(10):1065-75. PubMed ID: 25088940
[TBL] [Abstract][Full Text] [Related]
40. Identification of LDH-A as a therapeutic target for cancer cell killing via (i) p53/NAD(H)-dependent and (ii) p53-independent pathways.
Allison SJ; Knight JR; Granchi C; Rani R; Minutolo F; Milner J; Phillips RM
Oncogenesis; 2014 May; 3(5):e102. PubMed ID: 24819061
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
